US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
AU5438499A
(en)
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
ES2274634T3
(es)
|
1998-08-29 |
2007-05-16 |
Astrazeneca Ab |
Compuestos de pirimidina.
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
IL150388A0
(en)
*
|
1999-12-24 |
2002-12-01 |
Aventis Pharma Ltd |
Azaindoles
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
CA2404532A1
(en)
*
|
2000-03-29 |
2001-10-04 |
Nancy J. Bump |
Method of identifying inhibitors of tie-2
|
US7369946B2
(en)
|
2000-03-29 |
2008-05-06 |
Abbott Gmbh & Co. Kg |
Method of identifying inhibitors of Tie-2
|
AU2000240570A1
(en)
*
|
2000-03-29 |
2001-10-08 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
TWI238824B
(en)
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0115109D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7427623B2
(en)
|
2001-09-11 |
2008-09-23 |
Smithkline Beecham Corporation |
4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
JP2005524672A
(ja)
|
2002-03-09 |
2005-08-18 |
アストラゼネカ アクチボラグ |
Cdk阻害活性を有するイミダゾリル置換ピリミジン誘導体
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
SG135051A1
(en)
*
|
2002-06-20 |
2007-09-28 |
Aventis Pharma Ltd |
Azaindoles
|
WO2004013141A1
(en)
|
2002-08-06 |
2004-02-12 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
EP1388541A1
(de)
*
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazine als Kinasehemmer
|
UA80171C2
(en)
*
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
KR100767854B1
(ko)
|
2003-03-12 |
2007-10-17 |
화이자 프로덕츠 인크. |
피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
EP1687309A1
(de)
|
2003-11-17 |
2006-08-09 |
Pfizer Products Inc. |
Pyrrolopyrimidinverbindungen, die sich zur behandlung von krebs eignen
|
WO2005074603A2
(en)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
US7534797B2
(en)
*
|
2004-04-02 |
2009-05-19 |
Osi Pharmaceuticals, Inc. |
6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
JP4842929B2
(ja)
*
|
2004-05-27 |
2011-12-21 |
ファイザー・プロダクツ・インク |
癌治療に有用なピロロピリミジン誘導体
|
JP2008520744A
(ja)
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
DE102005016634A1
(de)
*
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
US20100216798A1
(en)
*
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
CA2623374A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
EP1983971A4
(de)
|
2006-01-25 |
2010-11-24 |
Synta Pharmaceuticals Corp |
Substituierte aromatische verbindungen für entzündungs- und immunbedingte verwendung
|
US7659283B2
(en)
*
|
2006-02-14 |
2010-02-09 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
|
AU2007347115A1
(en)
|
2006-04-04 |
2008-10-23 |
The Regents Of The University Of California |
PI3 kinase antagonists
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
AU2007338574A1
(en)
*
|
2006-11-01 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
EP2124951B1
(de)
*
|
2006-12-21 |
2014-05-21 |
Vertex Pharmaceuticals Inc. |
5-cyan0-4- (pyrrolo [2, 3b]pyridine-3-l)-pyrimidinderivate als proteinkinasehemmer
|
AU2008276063B2
(en)
|
2007-07-17 |
2013-11-28 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
KR101897881B1
(ko)
|
2008-01-04 |
2018-09-12 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
US8119637B2
(en)
*
|
2008-06-10 |
2012-02-21 |
Plexxikon Inc. |
Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
EP2358720B1
(de)
*
|
2008-10-16 |
2016-03-02 |
The Regents of The University of California |
Heteroarylkinasehemmer mit kondensierten ringen
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
AR078033A1
(es)
|
2009-04-03 |
2011-10-12 |
Plexxikon Inc |
Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
|
EP2417123A2
(de)
*
|
2009-04-06 |
2012-02-15 |
Agios Pharmaceuticals, Inc. |
Therapeutische zusammensetzungen und damit in zusammenhang stehende anwendungsverfahren
|
EP2427195B1
(de)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclische verbindungen und ihre verwendung
|
EP2448582B1
(de)
|
2009-06-29 |
2017-04-19 |
Agios Pharmaceuticals, Inc. |
Chinolin-8-sulfonamid-derivate mit einer aktivität gegen krebs
|
ES2618630T3
(es)
|
2009-06-29 |
2017-06-21 |
Agios Pharmaceuticals, Inc. |
Composiciones terapéuticas y métodos de uso relacionados
|
PL2473510T3
(pl)
*
|
2009-09-03 |
2014-11-28 |
Bristol Myers Squibb Co |
Inhibitory JAK2 i ich zastosowanie do leczenia chorób mieloproliferacyjnych i nowotworu
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
NZ599866A
(en)
|
2009-11-06 |
2014-09-26 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CN102712648A
(zh)
*
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
CN103002738A
(zh)
|
2010-05-21 |
2013-03-27 |
英特利凯恩有限责任公司 |
用于激酶调节的化学化合物、组合物和方法
|
AU2011326071A1
(en)
|
2010-11-08 |
2013-05-23 |
Lycera Corporation |
N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
MX2013006900A
(es)
|
2010-12-17 |
2013-10-17 |
Agios Pharmaceuticals Inc |
Nuevos derivados n-(4-(azetidina-1-carbonil)fenil)-(hetero-)arilsu lfonamida como moduladores piruvato quinasa m2 (pmk2).
|
CA2822432C
(en)
|
2010-12-21 |
2019-09-24 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
PE20141360A1
(es)
|
2011-02-07 |
2014-10-13 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
CN103492390A
(zh)
*
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
WO2012151440A1
(en)
|
2011-05-03 |
2012-11-08 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
|
HUE039269T2
(hu)
|
2011-05-03 |
2018-12-28 |
Agios Pharmaceuticals Inc |
Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TW201311663A
(zh)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
雜環化合物及其用途
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6236068B2
(ja)
|
2012-05-08 |
2017-11-22 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
RORγ活性を阻害し疾患を治療するためのテトラヒドロナフチリジンおよび関連二環式化合物
|
EP2847198B1
(de)
|
2012-05-08 |
2016-12-14 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridinsulfonamid und verwandte verbindungen zur verwendung als ror-gamma-agonisten und behandlung von krankheiten
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
WO2014015905A1
(en)
*
|
2012-07-26 |
2014-01-30 |
Glaxo Group Limited |
2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
US9487485B2
(en)
|
2013-02-28 |
2016-11-08 |
Takeda Pharmaceutical Company Limited |
Method for producing sulfonyl chloride compound
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014139144A1
(en)
|
2013-03-15 |
2014-09-18 |
Agios Pharmaceuticals, Inc. |
Therapeutic compounds and compositions
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9586967B2
(en)
|
2013-11-08 |
2017-03-07 |
Ono Pharmaceutical Co., Ltd. |
Pyrrolo pyrimidine derivative
|
CA2834528A1
(en)
*
|
2013-11-26 |
2015-05-26 |
Pharmascience Inc. |
Protein kinase inhibitors
|
WO2015095792A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションLycera Corporation |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
AU2015231413B2
(en)
|
2014-03-19 |
2020-04-23 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
US10189777B2
(en)
|
2014-05-05 |
2019-01-29 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
CA2975997A1
(en)
|
2015-02-11 |
2016-08-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
US11234976B2
(en)
|
2015-06-11 |
2022-02-01 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
JP5826964B1
(ja)
*
|
2015-06-18 |
2015-12-02 |
タマ化学工業株式会社 |
ピリジン−3−スルホニルクロリドの製造方法
|
MX2018003058A
(es)
|
2015-09-14 |
2018-08-01 |
Infinity Pharmaceuticals Inc |
Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
|
US10344000B2
(en)
|
2015-10-27 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
|
JP2018531958A
(ja)
|
2015-10-27 |
2018-11-01 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用
|
EP3368539B1
(de)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituierte indazolverbindungen als ror gamma t-inhibitoren und deren verwendungen
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN107513068A
(zh)
*
|
2016-06-16 |
2017-12-26 |
中国科学院上海药物研究所 |
一种具有fgfr抑制活性的新型化合物及其制备和应用
|
WO2017220477A1
(en)
*
|
2016-06-21 |
2017-12-28 |
Nerviano Medical Sciences S.R.L. |
N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
|
JP7054681B2
(ja)
|
2016-06-24 |
2022-04-14 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
組合せ療法
|
IL265028B
(en)
*
|
2016-09-16 |
2022-09-01 |
Vitae Pharmaceuticals Llc |
Inhibitors of the menin-mil interaction
|
CN110483523B
(zh)
*
|
2019-08-27 |
2022-11-22 |
药雅科技(上海)有限公司 |
一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
JP2023549540A
(ja)
|
2020-11-18 |
2023-11-27 |
デシフェラ・ファーマシューティカルズ,エルエルシー |
Gcn2およびperkキナーゼ阻害剤およびその使用方法
|
WO2023202625A1
(zh)
*
|
2022-04-20 |
2023-10-26 |
深圳福沃药业有限公司 |
Fgfr2抑制剂及使用方法
|
CN117402161A
(zh)
*
|
2022-07-06 |
2024-01-16 |
上海科恩泰生物医药科技有限公司 |
一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
|